Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cardiosphere-derived products.
Research focus: Treatment of heart disease associated with Duchenne.
Status: Phase 1/2 study.
“Our research intends to halt cardiomyopathy progression in Duchenne which is a devastating complication that affects all most all those affected by the disease. We appreciate working with an innovative and forward-thinking organization like CureDuchenne that continues to fund impactful research to find treatments for Duchenne.” — Dr. Linda Marbán, Chief Executive Officer of Capricor.